Literature DB >> 19799437

3D pharmacophore mapping using 4D QSAR analysis for the cytotoxicity of lamellarins against human hormone-dependent T47D breast cancer cells.

Poonsiri Thipnate1, Jianzhong Liu, Supa Hannongbua, A J Hopfinger.   

Abstract

4D quantitative structure-activity relationship (QSAR) and 3D pharmacophore models were built and investigated for cytotoxicity using a training set of 25 lamellarins against human hormone dependent T47D breast cancer cells. Receptor-independent (RI) 4D QSAR models were first constructed from the exploration of eight possible receptor-binding alignments for the entire training set. Since the training set is small (25 compounds), the generality of the 4D QSAR paradigm was then exploited to devise a strategy to maximize the extraction of binding information from the training set and to also permit virtual screening of diverse lamellarin chemistry. 4D QSAR models were sought for only six of the most potent lamellarins of the training set as well as another subset composed of lamellarins with constrained ranges in molecular weight and lipophilicity. This overall modeling strategy has permitted maximizing 3D pharmacophore information from this small set of structurally complex lamellarins that can be used to drive future analog synthesis and the selection of alternate scaffolds. Overall, it was found that the formation of an intermolecular hydrogen bond and the hydrophobic interactions for substituents on the E ring most modulate the cytotoxicity against T47D breast cancer cells. Hydrophobic substitutions on the F-ring can also enhance cytotoxic potency. A complementary high-throughput virtual screen to the 3D pharmacophore models, a 4D fingerprint QSAR model, was constructed using absolute molecular similarity. This 4D fingerprint virtual high-throughput screen permits a larger range of chemistry diversity to be assayed than with the 4D QSAR models. The optimized 4D QSAR 3D pharmacophore model has a leave-one-out cross-correlation value of xv-r2 = 0.947, while the optimized 4D fingerprint virtual screening model has a value of xv-r2 = 0.719. This work reveals that it is possible to develop significant QSAR, 3D pharmacophore, and virtual screening models for a small set of lamellarins showing cytotoxic behavior in breast cancer screens that can guide future drug development based upon lamellarin chemistry.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19799437      PMCID: PMC2798151          DOI: 10.1021/ci9002427

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  22 in total

1.  Synthesis and structure-activity relationship study of lamellarin derivatives.

Authors:  Fumito Ishibashi; Shinji Tanabe; Tatsuya Oda; Masatomo Iwao
Journal:  J Nat Prod       Date:  2002-04       Impact factor: 4.050

2.  Estimation of molecular similarity based on 4D-QSAR analysis: formalism and validation.

Authors:  J S Duca; A J Hopfinger
Journal:  J Chem Inf Comput Sci       Date:  2001 Sep-Oct

3.  4D-fingerprints, universal QSAR and QSPR descriptors.

Authors:  Craig L Senese; J Duca; D Pan; A J Hopfinger; Y J Tseng
Journal:  J Chem Inf Comput Sci       Date:  2004 Sep-Oct

4.  4D-fingerprint categorical QSAR models for skin sensitization based on the classification of local lymph node assay measures.

Authors:  Yi Li; Yufeng J Tseng; Dahua Pan; Jianzhong Liu; Petra S Kern; G Frank Gerberick; Anton J Hopfinger
Journal:  Chem Res Toxicol       Date:  2007-01       Impact factor: 3.739

5.  Categorical QSAR Models for skin sensitization based upon local lymph node assay classification measures part 2: 4D-fingerprint three-state and two-2-state logistic regression models.

Authors:  Yi Li; Dahua Pan; Jianzhong Liu; Petra S Kern; G Frank Gerberick; Anton J Hopfinger; Yufeng J Tseng
Journal:  Toxicol Sci       Date:  2007-08-03       Impact factor: 4.849

6.  QSAR analyses of skin penetration enhancers.

Authors:  Manisha Iyer; Tao Zheng; A J Hopfinger; Yufeng J Tseng
Journal:  J Chem Inf Model       Date:  2007-05-02       Impact factor: 4.956

7.  Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships.

Authors:  Esther Marco; William Laine; Christelle Tardy; Amélie Lansiaux; Masatomo Iwao; Fumito Ishibashi; Christian Bailly; Federico Gago
Journal:  J Med Chem       Date:  2005-06-02       Impact factor: 7.446

8.  Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D.

Authors:  Jérôme Kluza; Miguel-Angel Gallego; Anne Loyens; Jean-Claude Beauvillain; José-Maria Fernandez Sousa-Faro; Carmen Cuevas; Philippe Marchetti; Christian Bailly
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

9.  Overcoming chemoresistance of non-small cell lung carcinoma through restoration of an AIF-dependent apoptotic pathway.

Authors:  M-A Gallego; C Ballot; J Kluza; N Hajji; A Martoriati; L Castéra; C Cuevas; P Formstecher; B Joseph; G Kroemer; C Bailly; P Marchetti
Journal:  Oncogene       Date:  2007-10-01       Impact factor: 9.867

10.  Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues.

Authors:  Christelle Tardy; Michaël Facompré; William Laine; Brigitte Baldeyrou; Dolores García-Gravalos; Andrés Francesch; Cristina Mateo; Alfredo Pastor; José A Jiménez; Ignacio Manzanares; Carmen Cuevas; Christian Bailly
Journal:  Bioorg Med Chem       Date:  2004-04-01       Impact factor: 3.641

View more
  2 in total

1.  3D pharmacophore mapping using 4D QSAR analysis for the cytotoxicity of lamellarins against human hormone-dependent T47D breast cancer cells.

Authors:  Poonsiri Thipnate; Jianzhong Liu; Supa Hannongbua; A J Hopfinger
Journal:  J Chem Inf Model       Date:  2009-10       Impact factor: 4.956

Review 2.  Two Decades of 4D-QSAR: A Dying Art or Staging a Comeback?

Authors:  Andrzej Bak
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.